| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.047 | 0.8 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |